Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy

Indian Journal of Ophthalmology

Volumn 57, Issue 6, 2009, Pages 419-422

  Zakir, Shaik M ^a   Shukla, M ^a   Simi, Zaka Ur Rab ^a   Ahmad, J ^b   Sajid, Mahmood ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Cortisol; Idiopathic central serous chorioretinopathy; Testosterone

Indexed keywords

BIOLOGICAL MARKER; HYDROCORTISONE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD; CENTRAL SEROUS RETINOPATHY; CIRCADIAN RHYTHM; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; PHYSIOLOGY; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; CENTRAL SEROUS CHORIORETINOPATHY; CIRCADIAN RHYTHM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; MALE; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TESTOSTERONE;

EID: 70449428683     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.57143     Document Type: Article

References (28)

1. Von Graefe A. Ueber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol 1866;12:211-215
2. Yannuzzi LA. Type: A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986;84:799-845.
3. Maumenee AE. Symposium on macular diseases: Clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol 1965;69:605-613
4. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63:1-139.
5. Klein ML, Van Buskirk EM, Friedman E. Experience with non- treatment of central serous choroidopathy. Arch Ophthalmol 1974;91:247-250
6. Garg SP, Dada T, Talwar D, Biswas NR. Endogenous Cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 1997;81:962-964
7. Bouzas EA, Karadimas P, Constantin JP. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47:431-448
8. Zumo B, Rosenfeld RS, Friedman M, Byers SO, Rosenman RH, Hellman L. Elevated daytime urinary excretion of testosterone glucuronide in men with the type A behavior patt ern. Psychosom Med 1984;46:223-225
9. Collins WP, et al. Radioimmunoassay of plasma testosterone. J Steroid Biochem 1972;3:333.
10. Katsimpris J, Donati G, Kapetanios A. Value of Indocyanine green angiography in detection of central serous chorioretinopathy. Klin Monatsbl Augenheilkd 2001;218:335-337
11. Gass JD. Stereoscopic atlas of macular diseases: Diagnosis and treatment. 2nd ed. St Louis: CV Mosby Co; 1977. p. 28-41.
12. Wessing A. Changing concept of central serous retinopathy and its treatment. Trans Am Acad Ophthalmol Otolaryngol 1973;77:OP275-80.
13. Abuel-Asrar AM. Central serous chorioretinopathy complicating systemic corticosteroid therapy. Eur J Ophthalmol 1997;7:297-300.
14. Schneider RH. New markers for type A behavior: Pupil size and platelet epinephrine. Psychosom Med 1985;47:89.
15. Dembroski TM, MacDougall JM, Shields JL. Physiologic reaction to social challenge in persons evidencing the type A coronary-prone behavior patt ern. J Hum Stress 1977;3:211-230
16. Manuk SB, Garland FN. Coronary-prone behavior pattern, task incentive and cardiovascular response. Psychophysiology 1979;16:136-143
17. Simpson MT, Olewine DA, Jenkins CD, Ramsey FH, Zyzanski SJ, Thomas G, et al. Exercise-induced catecholamines and platelet aggregation in the coronary-prone behavior pattern. Psychosom Med 1974;36:476-487
18. Williams RB. Physiological mechanisms underlying disease. In: Gentry WD, Williams RB Jr, editors. Psychological aspects of myocardial infarction and coronary care. St Louis: CV Mosby; 1975. chap 8.
19. Williams Jr RB, Lane JD, Kuhn CM, Melosh W, White AD, Schanberg SM. Type A behavior and elevated physiological and neuroendocrine responses to cognitive tasks. Science 1982;218: 483-485
20. Friedman M, Byers SO, Diamant J, Rosenman RH. Plasma catecholamine response of coronary prone subjects (type A) to specific challenge. Metabolismn 1975;4:205-210
21. Friedman M, St George S, Byers SO, Rosenman RH. Excretion of catecholamines, 17-ketosteroids, 17-hydroxycorticoids, and 5-hydroxyindole in men exhibiting a particular behavior (patt ern A) associated with high incidence of clinical coronary artery disease. J Clin Invest 1960;39:758-764
22. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996;103:2070-2080
23. Spitznas M, Huke J. Number, shape, and topography of leakage points in acute type I central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1987;225:437-440
24. Kapetanios AD, Donati G, Bouzas E, Mastorakos G, Pournaras CJ. Serous central chorioretinopathy and endogenous hypercortisolemia. Klin Monatsbl Augenheilkd 1998;212:343-344
25. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men: A 13- year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997;146:609-617
26. Ahad MA, Chua CN, Evans NM. Central serous chorioretinopathy associated with testosterone therapy. Eye 2006;20:503-505
27. Grieshaber MC, Staub JJ, Flammer J. The potential role of testosterone in central serous chorioretinopathy. Br J Ophthalmol 2007;91:118-119
28. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003;110:698-703.